Allarity Therapeutics: Material Agreements, Equity Sales, Bylaw Changes
Ticker: ALLR · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1860657
Complexity: moderate
Sentiment: mixed
Topics: equity-sales, debt, corporate-governance, material-agreement
TL;DR
**Allarity Therapeutics just made major financial and structural changes, including selling new shares and altering shareholder rights.**
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on January 19, 2024, reporting several significant events that occurred on January 18, 2024. These include entering into a material definitive agreement, creating a direct financial obligation, and engaging in unregistered sales of equity securities. The company also made material modifications to the rights of security holders and amended its articles of incorporation or bylaws. This matters to investors because these actions often indicate a company is raising capital, potentially diluting existing shares, or restructuring its financial obligations, which can impact stock value.
Why It Matters
These actions suggest Allarity Therapeutics is undergoing significant financial and structural changes, which could impact its capital structure, ownership dilution, and future operational flexibility.
Risk Assessment
Risk Level: high — The filing indicates multiple significant changes including unregistered equity sales and modifications to shareholder rights, which often signal potential dilution and increased financial risk for existing investors.
Analyst Insight
A smart investor would thoroughly investigate the details of the 'Material Definitive Agreement,' 'Direct Financial Obligation,' and 'Unregistered Sales of Equity Securities' once the full exhibits are available to understand the potential dilution, debt burden, and strategic implications for Allarity Therapeutics, Inc. before making any investment decisions.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of the earliest event reported in the 8-K
- January 19, 2024 (date) — date the 8-K was filed
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 18, 2024' section.
What types of material events did Allarity Therapeutics, Inc. report in this 8-K?
Allarity Therapeutics, Inc. reported several material events, including 'Entry into a Material Definitive Agreement,' 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant,' 'Unregistered Sales of Equity Securities,' 'Material Modifications to Rights of Security Holders,' and 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as listed under 'ITEM INFORMATION'.
What is the business address of Allarity Therapeutics, Inc.?
The business address of Allarity Therapeutics, Inc. is '24 School Street, 2nd Floor, Boston, MA 02108', as specified in the 'BUSINESS ADDRESS' section of the filing.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is '0001860657', found under 'COMPANY DATA: CENTRAL INDEX KEY'.
Under which SEC Act was this 8-K filed?
This 8-K was filed under the '1934 Act', as indicated in the 'FILING VALUES: SEC ACT' section.
Filing Stats: 1,950 words · 8 min read · ~7 pages · Grade level 12.7 · Accepted 2024-01-19 17:29:17
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
- $440,000 — ote in an aggregate principal amount of $440,000 (the "Principal Amount") due on January
- $400,000 — ts") for an aggregate purchase price of $400,000, representing an approximately 10% orig
- $600,000 — itional closings of up to an additional $600,000 of notes in the aggregate. Interest
- $0.4476 — f the Note. The set conversion price is $0.4476 per share. The number of shares to be i
- $250,000 — d from (i) incurring any debt exceeding $250,000 in total; (ii) creating any liens on th
- $50,000 — rting officers and directors, capped at $50,000 in total; (v) repurchasing or acquiring
- $15,000 — hase Agreement. We agreed to pay up to $15,000 of reasonable attorneys' fees and expen
- $1.00 — t to change the "Conversion Price" from $1.00 to $0.4476. The information set forth
Filing Documents
- ea191856-8k_allarity.htm (8-K) — 62KB
- ea191856ex3-1_allarity.htm (EX-3.1) — 9KB
- ea191856ex4-1_allarity.htm (EX-4.1) — 133KB
- ea191856ex10-1_allarity.htm (EX-10.1) — 271KB
- 0001213900-24-004946.txt ( ) — 757KB
- allr-20240118.xsd (EX-101.SCH) — 3KB
- allr-20240118_lab.xml (EX-101.LAB) — 33KB
- allr-20240118_pre.xml (EX-101.PRE) — 22KB
- ea191856-8k_allarity_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Exhibit Description 3.1 Fifth Certificate of Amendment (Series A Preferred Stock) 4.1 Senior Convertible Note 10.1 Securities Purchase Agreement, dated as of January 18, 2024, by and between the Company and the Purchaser listed on the signature page attached thereto 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: January 19, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer 4